This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $528,179 to the University of Miami to investigate novel strategies for improving neovascularization in peripheral arterial disease and critical limb ischemia. The primary aims are to: 1) determine if extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, 2) evaluate the impact of modulating the DHCR24 enzyme in myeloid cells on limb perfusion and arteriogenesis in animal models of hindlimb ischemia, and 3) assess how loss of DHCR24 in myeloid cells regulates their crosstalk with endothelial cells. This research aims to advance the scientific understanding of monocyte-driven mechanisms that could lead to improved treatments for peripheral artery disease and critical limb ischemia. The award period spans from March 4, 2025 through December 31, 2028.
Generated 3/25/25, 1:45 AM